Indian pharma major Dr Reddy's Laboratories said today that a US District Court has issued a temporary restraining order on the sale and commercialisation of its generic Buprenorphine and Naloxone sublingual film in the American market.
It is indicated for treatment of opioid dependence.
Dr Reddy's said in a BSE filing that the company remains confident in its legal positions on this patent.
"The court order does not include a prohibition on commercial manufacturing of the product," it added.
The company said that following the launch of its generic Buprenorphine and Naloxone sublingual film in the US market, "the US District Court for the District of New Jersey has received and reviewed an emergency application from the plaintiffs in the current patent litigation for a temporary restraining order and preliminary injunction against Dr Reddy's".
The Hyderabad-based firm added that pending a hearing and decision on the injunction application, the court has issued a temporary restraining order against the company for further sales and commercialisation of the product.
"The plaintiffs will be required to post a bond or other security totalling USD 18 million to satisfy any losses or damages incurred by Dr Reddy's during the period of the temporary restraining order," it added.
The court has scheduled an expedited hearing of the preliminary injunction for June 28, and a ruling is expected soon thereafter, it added.
The proceeding only involves one patent. The company "remains confident in its legal positions on this patent and believes it will prevail on the issues raised with respect to the application for injunction," Dr Reddy's said.
The company had said yesterday that it has received final approval from the US Food and Drug Administration (USFDA) and is launching Buprenorphine and Naloxone Sublingual film, (2 mg/0.5 mg, 4 mg/1 mg, 8 mg/2 mg, and 12 mg/3 mg) -- a generic version of Indivior UK's Suboxone sublingual film in the US market.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app